Power3 Alleges Insider Trading by Two of its Largest Shareholders | GenomeWeb

This story originally ran May 6.

By Tony Fong

Protein biomarker firm Power3 Medical Products is suing two shareholders, alleging insider trading.

The lawsuit was filed on April 14 in United States District Court for the Southern District of Texas, located in Houston, and specifically claims that the shareholders, Richard Kraniak and Roger Kazanowski, illegally profited from insider information pertaining to Power3's acquisition of stem cell firm StemTronix.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.